See more : Bloomios, Inc. (BLMS) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunoCellular Therapeutics, Ltd. (IMUC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunoCellular Therapeutics, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- YouGov plc (YUGVF) Income Statement Analysis – Financial Results
- Bangkok Commercial Property Fund (BKKCP.BK) Income Statement Analysis – Financial Results
- Priortech Ltd (PRTC.TA) Income Statement Analysis – Financial Results
- Smartgroup Corporation Ltd (STGXF) Income Statement Analysis – Financial Results
- Spod Lithium Corp. (EEEXF) Income Statement Analysis – Financial Results
ImmunoCellular Therapeutics, Ltd. (IMUC)
About ImmunoCellular Therapeutics, Ltd.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 47.77K | 75.11K | 36.19K | 47.66K | 50.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -47.77K | -75.11K | -36.19K | -47.66K | -50.40K | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 580.91K | 1.23M | 1.30M | 696.72K | 17.13M | 19.11M | 10.90M | 5.97M | 5.34M | 7.71M | 4.99M | 2.29M | 962.53K | 1.30M | 77.86K | 772.20K | 152.76K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 308.43K | 143.96K | 4.03M | 5.01M | 4.62M | 3.89M | 4.12M | 4.12M | 3.64M | 2.84M | 1.99M | 1.88M | 1.30M | 459.26K | 54.13K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 554.03K | 632.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 946.02K | 4.10M | 0.00 | 0.00 | 0.00 |
| SG&A | 1.24M | 1.66M | 1.31M | 756.27K | 4.03M | 5.01M | 4.62M | 3.89M | 4.12M | 4.12M | 3.64M | 2.84M | 1.99M | 1.88M | 2.24M | 4.56M | 54.13K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 7.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.82M | 2.89M | 2.61M | 1.45M | 21.15M | 24.11M | 15.51M | 9.86M | 9.46M | 11.83M | 8.63M | 5.14M | 2.95M | 3.18M | 2.32M | 5.34M | 206.89K | 0.00 | 0.00 |
| Cost & Expenses | 1.82M | 2.89M | 2.61M | 1.45M | 21.15M | 24.11M | 15.51M | 9.86M | 9.46M | 11.83M | 8.63M | 5.14M | 2.95M | 3.18M | 2.32M | 5.34M | 206.89K | 0.00 | 0.00 |
| Interest Income | 0.00 | 0.00 | 8.46 | 0.00 | 4.68K | 24.38K | 19.86K | 13.92K | 17.35K | 8.61K | 4.35K | 4.11K | 22.05K | 116.55K | 162.04K | 30.05K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 550.73K | 0.00 | 8.46K | 0.00 | 882.68K | 1.31M | 133.91K | 62.68K | 0.00 | 397.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 2.61M | 1.94M | 47.77K | 75.11K | -32.88K | 13.92K | 17.35K | 45.82K | 20.36K | 3.63K | 3.40K | 2.08K | 1.46M | -117.48K | 39.12K | 0.00 | 0.00 |
| EBITDA | -1.06M | -2.44M | -1.00 | 0.00 | -13.38M | -20.20M | -12.53M | -9.33M | -8.80M | -14.45M | -5.70M | -6.15M | -2.62M | -3.06M | -864.39K | -5.15M | -246.00K | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -881.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.82M | -2.89M | -2.61M | -1.45M | -21.15M | -24.11M | -15.51M | -9.86M | -9.46M | -11.83M | -8.63M | -5.14M | -2.65M | -3.18M | -2.32M | -5.37M | -206.89K | 0.00 | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -882.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 203.58K | 238.41K | -65.71K | 0.00 | 6.84M | 2.03M | 2.72M | 481.01K | 659.76K | -2.67M | 0.00 | 0.00 | 22.05K | 0.00 | -1.29M | 117.48K | -39.12K | 0.00 | 0.00 |
| Income Before Tax | -1.61M | -2.65M | -2.68M | -1.45M | -14.31M | -22.09M | -12.79M | -9.38M | -8.80M | -14.50M | -5.72M | -6.15M | -2.63M | -3.06M | -3.61M | -5.22M | -246.00K | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -875.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | -228.49K | -2.61K | -1.94K | 4.20M | 1.31M | 133.91K | 15.03K | -50.40K | 351.47K | -2.91M | 1.01M | -22.05K | -116.55K | -162.04K | -64.91K | 0.00 | 0.00 | 0.00 |
| Net Income | -1.61M | -2.65M | -2.68M | -1.45M | -18.52M | -23.40M | -12.92M | -9.39M | -8.75M | -14.50M | -5.72M | -6.15M | -2.63M | -3.06M | -3.61M | -5.15M | -246.00K | 0.00 | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -875.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.02 | -0.06 | -0.03 | -4.42 | -83.60 | -59.29 | -64.10 | -64.48 | -112.58 | -83.35 | -128.21 | -76.57 | -97.60 | -133.22 | -236.02 | -14.33 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.06 | -0.03 | -4.42 | -83.60 | -59.29 | -64.10 | -64.48 | -112.58 | -83.35 | -128.21 | -76.57 | -97.60 | -133.22 | -236.02 | -14.33 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 113.27M | 113.27M | 45.43M | 45.08M | 4.19M | 279.89K | 218.01K | 146.52K | 135.70K | 128.75K | 68.63K | 47.97K | 34.30K | 31.35K | 27.13K | 21.83K | 17.17K | 178.56M | 0.00 |
| Weighted Avg Shares Out (Dil) | 113.27M | 113.27M | 45.43M | 45.08M | 4.19M | 279.89K | 218.01K | 146.52K | 135.70K | 128.75K | 68.63K | 47.97K | 34.30K | 31.35K | 27.13K | 21.83K | 17.17K | 178.56M | 0.00 |
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613
MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized...
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021.
Source: https://incomestatements.info
Category: Stock Reports